YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
暂无分享,去创建一个
I. Wistuba | E. Felip | C. Behrens | L. Paz-Ares | M. Cuadrado | F. Lecanda | M. Pajares | X. Bustelo | M. Sanchez-Cespedes | A. Calvo | I. Gil-Bazo | L. Montuenga | R. Pio | J. Agorreta | J. García-Pedrero | J. Rodrigo | K. Valencia | D. Ajona | I. Ferrer | A. Remírez | F. Hermida-Prado | C. Bértolo | R. Granda-Díaz | I. Garmendia | D. Alameda | Haritz Moreno | C. Sainz | Amaya Lavín
[1] L. Paz-Ares,et al. Abstract LB-084: Dasatinib reduces tumor growth in xenograft models derived from human lung tumors with YES1 overexpression , 2018, Experimental and Molecular Therapeutics.
[2] H. Varmus,et al. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics , 2018, Proceedings of the National Academy of Sciences.
[3] S. Vicent,et al. Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16‐mediated Effects , 2018, American journal of respiratory and critical care medicine.
[4] M. Ladanyi,et al. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance , 2018, Clinical Cancer Research.
[5] Roy S. Herbst,et al. The biology and management of non-small cell lung cancer , 2018, Nature.
[6] P. Meltzer,et al. Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers , 2018, Oncotarget.
[7] S. Menéndez,et al. Dysregulation of Mir-196b in Head and Neck Cancers Leads to Pleiotropic Effects in the Tumor Cells and Surrounding Stromal Fibroblasts , 2017, Scientific Reports.
[8] I. Wistuba,et al. Abstract LB-117: Dasatinib for the treatment of patients with non-small cell lung cancer harboring YES1 amplification , 2017 .
[9] Amanda R. Kulick,et al. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. , 2017, Cancer research.
[10] P. Delrée,et al. The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling , 2017, Scientific Reports.
[11] M. Baccarani,et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? , 2017, Nature Reviews Clinical Oncology.
[12] Hiromasa Yamamoto,et al. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer , 2017, PloS one.
[13] D. Weaver,et al. Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.
[14] Chandra Sekhar Pedamallu,et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.
[15] J. Martinez-Climent,et al. Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations , 2015, BMC Genomics.
[16] M. Meyerson,et al. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer , 2015, ACS chemical biology.
[17] G. Giaccone,et al. Refining the treatment of NSCLC according to histological and molecular subtypes , 2015, Nature Reviews Clinical Oncology.
[18] R. Herbst,et al. Lung Cancer in the Era of Precision Medicine , 2015, Clinical Cancer Research.
[19] Kazuro Furukawa,et al. Ganglioside GD3 Enhances Invasiveness of Gliomas by Forming a Complex with Platelet-derived Growth Factor Receptor α and Yes Kinase* , 2015, The Journal of Biological Chemistry.
[20] P. Friedl,et al. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells , 2015 .
[21] A. Harris,et al. TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC , 2014, Molecular Cancer Research.
[22] P. Hammerman,et al. Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] G. Altavilla,et al. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. , 2013, Lung cancer.
[24] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[25] T. Yano,et al. Yes is a central mediator of cell growth in malignant mesothelioma cells. , 2012, Oncology reports.
[26] C. Perou,et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. , 2012, Cancer cell.
[27] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[28] I. Wistuba,et al. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[30] D. Wheeler,et al. Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor , 2012, Oncogene.
[31] R. Veale,et al. Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes. , 2011, World journal of gastroenterology.
[32] M. Meyerson,et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. , 2011, Cancer discovery.
[33] Jean A. Boutin,et al. Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells , 2011, PloS one.
[34] S. Lippman,et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. W. Kim,et al. Elevated c-Src and c-Yes expression in malignant skin cancers , 2010, Journal of experimental & clinical cancer research : CR.
[36] E. Haura,et al. Src inhibitors in lung cancer: current status and future directions. , 2010, Clinical lung cancer.
[37] E. Haura,et al. Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.
[38] Laura Tolosi,et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.
[39] D. Ladant,et al. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. , 2007, Cancer research.
[40] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[41] G. Gallick,et al. Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.
[42] I. Wistuba,et al. MA17.10 YES1 Kinase is a New Therapeutic Target in Non-small Cell Lung Cancer , 2017 .
[43] J. Inazawa,et al. Novel targets for the 18p11.3 amplification frequently observed in esophageal squamous cell carcinomas. , 2002, Carcinogenesis.